Singapore-based biotechnology company CytoMed Therapeutics has signed a five-year business and research collaboration agreement (BRCA) with SunAct Cancer Institute for a Phase II clinical trial in India.
The trial will investigate the efficacy, safety, tolerability and potency of CytoMed’s allogeneic gamma delta T cells in treating various cancers, including solid tumours.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Both entities will jointly sponsor the clinical trial, which will be led by SunAct founder, medical oncologist and immunotherapy specialist Dr Vijay Patil.
Dr Patil said: “This collaboration with CytoMed will provide an alternative treatment for a wide range of solid cancers at a reduced cost to an increasing host of the population of India suffering from the effects of cancer.
“We aim to provide much-needed access to and treatment for cancer at an affordable cost and to contribute to an increasing and much-needed global data pool in our quest for a solution to fight cancer.”
Under the BRCA, CytoMed will provide scientific and technical support for the clinical trial, as well as manufacture the allogeneic gamma delta T cells.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSunAct and Dr Patil will offer their local expertise, knowledge of Indian regulations, and access to healthcare resources and patient populations.
CytoMed chairman Peter Choo said: “CytoMed’s collaboration with SunAct is timely and complements our core focus of harnessing CytoMed’s proprietary off-the-shelf technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers at affordable cost.
“We are excited to work with Dr Vijay Patil in our goal to accelerate the therapeutic application of CytoMed’s patented allogeneic gamma delta T-Cells (Patent Number: MY-200528-A; ZL 2018 8 0023646.8; US 11,629,333 B2) in an increasing population of cancer patients in India and around the world.”
Founded in 2018, CytoMed works to create novel cell-based cancer immunotherapies using gamma delta T cell and gamma delta Natural Killer T cell technologies.
